 | |
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C13H16N2O |
| Molar mass | 216.284 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Dianicline (SSR-591,813) is a drug developed bySanofi-Aventis which acts as apartial agonist at neuralnicotinic acetylcholine receptors. It is subtype-selective, binding primarily to theα4β2subtype. It is being developed as a medication for the treatment ofnicotine dependence to assist insmoking cessation.[1] Dianicline is very similar to the already marketed drugvarenicline and it is unclear what advantages it will have over the older drug, although it may have an improved side effect profile. It has been through human trials up to Phase II, although results have not yet been reported. Drug development has been discontinued after reporting of unfavourable results during Phase III trials.[2][3][4]
